FDA Approves GI Panels for QIAstat-Dx Rise Platform
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 hours ago
0mins
Should l Buy QGEN?
Source: Newsfilter
- FDA Approval Milestone: The FDA's clearance of the GI panels for the QIAstat-Dx Rise platform allows laboratories to run both respiratory and gastrointestinal panels on a single system, significantly enhancing testing efficiency and flexibility, which is expected to boost QIAGEN's competitiveness in the molecular diagnostics market.
- High-Throughput Automation: The QIAstat-Dx Rise platform can process up to 160 tests per day with less than one minute of hands-on time per test, and this efficient automation design will help laboratories reduce labor costs and improve operational efficiency.
- Expanded Testing Menu: This approval brings the total number of FDA clearances for the QIAstat-Dx portfolio to nine in the past 24 months, further solidifying its leadership position in the U.S. market and laying the groundwork for future product expansions.
- Clinical Decision Support: By providing rapid test results, the QIAstat-Dx system enables clinicians to quickly identify the cause of infections in patients with similar symptoms, thereby supporting timely treatment decisions and alleviating the burden on healthcare systems.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QGEN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QGEN
Wall Street analysts forecast QGEN stock price to rise
14 Analyst Rating
8 Buy
6 Hold
0 Sell
Moderate Buy
Current: 43.330
Low
45.00
Averages
50.57
High
55.00
Current: 43.330
Low
45.00
Averages
50.57
High
55.00
About QGEN
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA Approves GI Panels for QIAstat-Dx Rise Platform
- FDA Approval Milestone: The FDA's clearance of the GI panels for the QIAstat-Dx Rise platform allows laboratories to run both respiratory and gastrointestinal panels on a single system, significantly enhancing testing efficiency and flexibility, which is expected to boost QIAGEN's competitiveness in the molecular diagnostics market.
- High-Throughput Automation: The QIAstat-Dx Rise platform can process up to 160 tests per day with less than one minute of hands-on time per test, and this efficient automation design will help laboratories reduce labor costs and improve operational efficiency.
- Expanded Testing Menu: This approval brings the total number of FDA clearances for the QIAstat-Dx portfolio to nine in the past 24 months, further solidifying its leadership position in the U.S. market and laying the groundwork for future product expansions.
- Clinical Decision Support: By providing rapid test results, the QIAstat-Dx system enables clinicians to quickly identify the cause of infections in patients with similar symptoms, thereby supporting timely treatment decisions and alleviating the burden on healthcare systems.
See More
Qiagen CEO Actively Evaluating Strategic Alternatives
- Strategic Review Process: Qiagen NV CEO Thierry Bernard stated that the company is collaborating with Moelis & Co. and Goldman Sachs to review its strategic alternatives, indicating an openness to future developments and aiming to optimize decision-making with professional advisory support.
- Increased Acquisition Interest: According to a Bloomberg report, Qiagen is evaluating strategic options, including a potential sale, and has engaged in discussions with several potential buyers recently, reflecting strong market interest in its business that could impact the company's market positioning and shareholder value.
- Stock Price Volatility: Following the news of acquisition talks, Qiagen's shares fell by 2%, indicating market uncertainty regarding the company's future strategy, which may affect investor confidence and short-term stock performance.
- Future Growth Targets: Qiagen aims for a 9% growth in 2026 and plans to launch new products to achieve $2 billion in revenue by 2028, demonstrating that the company remains focused on long-term growth despite the ongoing acquisition interest.
See More
Surge in Options Trading Volume for nLight and Qiagen
- nLight Options Volume: nLight Inc (Ticker: LASR) has seen an options trading volume of 19,761 contracts today, equating to approximately 2 million shares, which represents a significant 135.9% of its average daily trading volume of 1.5 million shares over the past month, indicating strong market interest in its future performance.
- High Strike Call Options: Within LASR, the $65 strike call option has been particularly active, with 15,609 contracts traded today, representing about 1.6 million shares, reflecting investor expectations for the stock's appreciation before the March 20, 2026 expiration, potentially influencing its price trajectory.
- Qiagen Options Volume: Qiagen NV (Ticker: QGEN) has recorded an options trading volume of 26,038 contracts today, translating to approximately 2.6 million shares, achieving 109.1% of its average daily trading volume of 2.4 million shares over the past month, showcasing market confidence in its future potential.
- High Strike Call Options: For QGEN, the $65 strike call option has seen a trading volume of 20,597 contracts today, representing around 2.1 million shares, indicating investor optimism for the stock's rise before the May 15, 2026 expiration, which could positively impact its stock price.
See More
HIVE Digital Technologies Reports Larger Than Expected Quarterly Losses
- Quarterly Losses: HIVE Digital Technologies reported a quarterly loss of $0.38 per share, significantly exceeding the analyst consensus estimate of a $0.07 loss, indicating substantial challenges in profitability that could undermine investor confidence.
- Sales Miss: The company's quarterly sales totaled $93.111 million, falling short of the analyst consensus estimate of $96.975 million, reflecting weak market demand that may lead to declining future performance.
- Stock Price Reaction: In pre-market trading, HIVE's shares fell by 2.3% to $2.16, indicating a negative investor reaction to the earnings report, which could impact the company's short-term financing capabilities.
- Overall Market Trend: U.S. stock futures were broadly lower, with Nasdaq 100 futures dropping over 150 points, reflecting a bearish market sentiment that may have a ripple effect on HIVE and other tech stocks.
See More
QIAGEN NV: TD Cowen Increases Price Target from $48 to $53
Target Price Increase: The target price for a specific stock has been raised to $53 from a previous $48.
Market Reaction: This adjustment reflects a positive outlook on the company's performance and potential growth.
See More
Qiagen Reports Strong Q4 2025 Earnings Exceeding Expectations
- Performance Exceeds Expectations: Qiagen reported net sales of $540 million in Q4 2025, growing 1% year-over-year, with adjusted EPS at $0.62, both surpassing company forecasts, indicating robust market performance.
- Growth Pillars Performance: The combined sales from Sample Technologies, QuantiFERON, QIAstat, QIAcuity, and QIAGEN Digital Insights reached $1.49 billion, reflecting an 8% increase, underscoring the sustained growth of its core business and enhancing competitive positioning.
- Cash Flow and Shareholder Returns: Free cash flow was $453 million, with over $1.1 billion returned to shareholders since 2024, demonstrating strong capital management and investment capabilities, alongside the introduction of an annual dividend to attract investors.
- Future Outlook: Management anticipates at least 5% sales growth and adjusted EPS of at least $2.50 for 2026, despite challenges from macroeconomic uncertainty and cautious customer spending, with new product launches expected to accelerate performance in the second half of the year.
See More
FDA Approves GI Panels for QIAstat-Dx Rise Platform
- FDA Approval Milestone: The FDA's clearance of the GI panels for the QIAstat-Dx Rise platform allows laboratories to run both respiratory and gastrointestinal panels on a single system, significantly enhancing testing efficiency and flexibility, which is expected to boost QIAGEN's competitiveness in the molecular diagnostics market.
- High-Throughput Automation: The QIAstat-Dx Rise platform can process up to 160 tests per day with less than one minute of hands-on time per test, and this efficient automation design will help laboratories reduce labor costs and improve operational efficiency.
- Expanded Testing Menu: This approval brings the total number of FDA clearances for the QIAstat-Dx portfolio to nine in the past 24 months, further solidifying its leadership position in the U.S. market and laying the groundwork for future product expansions.
- Clinical Decision Support: By providing rapid test results, the QIAstat-Dx system enables clinicians to quickly identify the cause of infections in patients with similar symptoms, thereby supporting timely treatment decisions and alleviating the burden on healthcare systems.
See More
Qiagen CEO Actively Evaluating Strategic Alternatives
- Strategic Review Process: Qiagen NV CEO Thierry Bernard stated that the company is collaborating with Moelis & Co. and Goldman Sachs to review its strategic alternatives, indicating an openness to future developments and aiming to optimize decision-making with professional advisory support.
- Increased Acquisition Interest: According to a Bloomberg report, Qiagen is evaluating strategic options, including a potential sale, and has engaged in discussions with several potential buyers recently, reflecting strong market interest in its business that could impact the company's market positioning and shareholder value.
- Stock Price Volatility: Following the news of acquisition talks, Qiagen's shares fell by 2%, indicating market uncertainty regarding the company's future strategy, which may affect investor confidence and short-term stock performance.
- Future Growth Targets: Qiagen aims for a 9% growth in 2026 and plans to launch new products to achieve $2 billion in revenue by 2028, demonstrating that the company remains focused on long-term growth despite the ongoing acquisition interest.
See More
Surge in Options Trading Volume for nLight and Qiagen
- nLight Options Volume: nLight Inc (Ticker: LASR) has seen an options trading volume of 19,761 contracts today, equating to approximately 2 million shares, which represents a significant 135.9% of its average daily trading volume of 1.5 million shares over the past month, indicating strong market interest in its future performance.
- High Strike Call Options: Within LASR, the $65 strike call option has been particularly active, with 15,609 contracts traded today, representing about 1.6 million shares, reflecting investor expectations for the stock's appreciation before the March 20, 2026 expiration, potentially influencing its price trajectory.
- Qiagen Options Volume: Qiagen NV (Ticker: QGEN) has recorded an options trading volume of 26,038 contracts today, translating to approximately 2.6 million shares, achieving 109.1% of its average daily trading volume of 2.4 million shares over the past month, showcasing market confidence in its future potential.
- High Strike Call Options: For QGEN, the $65 strike call option has seen a trading volume of 20,597 contracts today, representing around 2.1 million shares, indicating investor optimism for the stock's rise before the May 15, 2026 expiration, which could positively impact its stock price.
See More
HIVE Digital Technologies Reports Larger Than Expected Quarterly Losses
- Quarterly Losses: HIVE Digital Technologies reported a quarterly loss of $0.38 per share, significantly exceeding the analyst consensus estimate of a $0.07 loss, indicating substantial challenges in profitability that could undermine investor confidence.
- Sales Miss: The company's quarterly sales totaled $93.111 million, falling short of the analyst consensus estimate of $96.975 million, reflecting weak market demand that may lead to declining future performance.
- Stock Price Reaction: In pre-market trading, HIVE's shares fell by 2.3% to $2.16, indicating a negative investor reaction to the earnings report, which could impact the company's short-term financing capabilities.
- Overall Market Trend: U.S. stock futures were broadly lower, with Nasdaq 100 futures dropping over 150 points, reflecting a bearish market sentiment that may have a ripple effect on HIVE and other tech stocks.
See More
QIAGEN NV: TD Cowen Increases Price Target from $48 to $53
Target Price Increase: The target price for a specific stock has been raised to $53 from a previous $48.
Market Reaction: This adjustment reflects a positive outlook on the company's performance and potential growth.
See More
Qiagen Reports Strong Q4 2025 Earnings Exceeding Expectations
- Performance Exceeds Expectations: Qiagen reported net sales of $540 million in Q4 2025, growing 1% year-over-year, with adjusted EPS at $0.62, both surpassing company forecasts, indicating robust market performance.
- Growth Pillars Performance: The combined sales from Sample Technologies, QuantiFERON, QIAstat, QIAcuity, and QIAGEN Digital Insights reached $1.49 billion, reflecting an 8% increase, underscoring the sustained growth of its core business and enhancing competitive positioning.
- Cash Flow and Shareholder Returns: Free cash flow was $453 million, with over $1.1 billion returned to shareholders since 2024, demonstrating strong capital management and investment capabilities, alongside the introduction of an annual dividend to attract investors.
- Future Outlook: Management anticipates at least 5% sales growth and adjusted EPS of at least $2.50 for 2026, despite challenges from macroeconomic uncertainty and cautious customer spending, with new product launches expected to accelerate performance in the second half of the year.
See More
